Zacks Research Weighs in on Pharma-Bio Serv FY2026 Earnings

Pharma-Bio Serv Inc. (OTCMKTS:PBSV) – Equities research analysts at Zacks Research cut their FY2026 earnings per share (EPS) estimates for Pharma-Bio Serv in a research report issued to clients and investors on Tuesday, June 16th. Zacks Research analyst B. Sorensen now forecasts that the company will earn $0.07 per share for the year, down from their prior estimate of $0.09. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.09 per share. Zacks Research also issued estimates for Pharma-Bio Serv’s Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at $0.02 EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at $0.04 EPS and FY2027 earnings at $0.11 EPS.

Pharma-Bio Serv Stock Performance

PBSV stock opened at $0.57 on Thursday. The firm’s 50-day moving average price is $0.53 and its two-hundred day moving average price is $0.54. Pharma-Bio Serv has a 12-month low of $0.43 and a 12-month high of $1.36.

Pharma-Bio Serv (OTCMKTS:PBSV) last posted its quarterly earnings results on Monday, June 15th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.70 million. Pharma-Bio Serv had a net margin of 0.68% and a return on equity of 0.56%.

About Pharma-Bio Serv

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc was founded in 1993 and is headquartered in Dorado, Puerto Rico.